Furthermore, galectin-9 decreased the expression of hepatocyte growth factor receptor (HGFR), fibroblast growth factor receptor 3 (FGFR3), phosphorylated epidermal growth factor receptor (p-EGFR), and phosphorylated epidermal growth factor-1 receptor (p-IGF-1R) in CCA cells, and changes in the activity of these receptor tyrosine kinases (RTKs) might have contributed to the antitumor effect. This evidence concerns the gene LGALS9 and cholangiocarcinoma.